Currently, the most common PET targets in patients with BC include HER (Trastuzumab and Pertuzumab) and vascular endothelial growth factor (VEGF-A—Bevacizumab) [62,63,64,65,66,67,68]. The gene discussed is VEGFA; the disease is breast cancer.